Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Other Non-Current Liabilities

Last Annual Value

263.51K

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Other Non-Current Liabilities

ANEB · NASDAQ
CompanyOther Non-Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
263.51K
N/AN/AN/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
8.16M
73.3%-17.1%N/A
0.00
N/AN/AN/A
500.00K
-34.5%N/AN/A
0.00
N/AN/AN/A
17.79M
N/AN/AN/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
90.36K
N/AN/AN/A
37.07M
24.7%131.7%N/A
314.00K
45.5%16.7%-2.1%
57.38M
1.9%N/AN/A
0.00
N/AN/AN/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72